Lung Function and CT Densitometry in Subjects with alpha-1-Antitrypsin Deficiency and Healthy Controls at 35 Years of

Eeva Piitulainen1, Laura Cano Montero, Meltem Nystedt-Düzakin

  • 11Departments of Respiratory Medicine and Allergology, Skåne University Hospital, Lund University , Malmö , Sweden.

COPD
|October 4, 2014
PubMed

Insights

Alpha-1-antitrypsin (AAT) deficiency in never-smokers shows no emphysema signs at age 35. However, AAT deficiency individuals who smoke show early emphysema indicators, highlighting smoking

Area of Science:

  • Pulmonary Medicine
  • Genetics
  • Radiology

Background:

  • Alpha-1-antitrypsin (AAT) deficiency is a known genetic risk factor for developing pulmonary emphysema.
  • A nationwide screening of Swedish newborns in 1972-1974 identified individuals with AAT deficiency.

Purpose of the Study:

  • To assess for early signs of emphysema in individuals with PiZZ and PiSZ AAT deficiency genotypes at 35 years of age.
  • To investigate the role of smoking as a modifier in the development of emphysema in AAT-deficient individuals.

Main Methods:

  • Pulmonary function tests (PFTs) and CT densitometry were performed on study participants.
  • Key metrics analyzed included the fifteenth percentile density (PD15) and relative area below -910 HU (RA-910).
  • Comparison was made between AAT-deficient genotypes (PiZZ, PiSZ) and PiMM control subjects, stratified by smoking status.

Main Results:

  • Never-smoking AAT-deficient individuals (PiZZ, PiSZ) exhibited normal lung function compared to never-smoking controls (PiMM).
  • PiZZ ever-smokers demonstrated significantly lower carbon monoxide transfer coefficient (KCO) compared to PiSZ and PiMM never-smokers.
  • CT densitometry revealed significantly lower PD15 in PiZZ ever-smokers compared to ever-smoking controls, suggesting early emphysematous changes.

Conclusions:

  • AAT deficiency alone does not appear to cause significant lung function impairment or emphysema in never-smokers by age 35.
  • Smoking exacerbates the effects of AAT deficiency, with PiZZ ever-smokers showing potential early signs of emphysema.
  • These findings underscore the critical role of smoking cessation in managing AAT deficiency to prevent or delay the onset of pulmonary emphysema.

Related Concept Videos

Pulmonary Function Tests01:25

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
1.1K
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
17
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.3K
Radiological Investigation II: MRI and Ventilation Perfusion Scan01:30

Radiological Investigation II: MRI and Ventilation Perfusion Scan

Description
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...
981